Roche’s Herceptin and Perjeta duo is already part of a well-established standard of care in early-stage HER2-positive breast ...

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with artificial-intelligence-powered analysis to provide what the company says could ...

The green light comes after a six-month priority review by the FDSA and is a big step up for Roche’s drug, which has the opportunity to build a presence in breast cancer ahead of earlier-to ...

Yesterday saw a new campaign group call for the UK government to override the patent on Roche's breast cancer drug Kadcyla if the ... ongoing Accelerated Access Review can help join up the UK's ...

To get screened for cervical cancer ... of a health care provider doing it for them. The US Food and Drug Administration has approved the first at-home self-collection device for cervical cancer ...

Stakeholders at the Roche Breast ... cancer patients, citing persistent challenges with late diagnosis and limited treatment options. “We have made significant advancements in research and drug ...

But, many of the biological medicines have gone off-patent. Now, India faces a new challenge: ensuring these biological ...

The artificial intelligence (AI) revolution is reshaping our world at an unprecedented pace. As AI technology evolves, it's ...

BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ...

Its lead candidates -- including REC-4881 for familial adenomatous polyposis and REC-7735 for breast cancer -- have demonstrated ... to disrupt traditional drug discovery strategies, Recursion ...